Wells Fargo raised the firm’s price target on Kestra Medical (KMTS) to $28 from $27 and keeps an Overweight rating on the shares. The firm notes the company reported Q2 sales in-line with its pre-announcement and raised FY26 sales guidance above the Q2 beat. Management highlighted an acceleration in WCD market growth, share capture, and improvement in in-network mix and RCM as driving its outlook.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical price target raised to $30 from $27 at Piper Sandler
- Kestra Medical Technologies: Strong Financial Performance and Market Leadership Drive Buy Rating
- Closing Bell Movers: Broadcom down 5%, Lululemon gains 10%
- Kestra Medical reports Q2 EPS (64c), consensus (57c)
- Kestra Medical raises FY26 revenue view to $91M from $88M, consensus $88.02M